These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 19237050

  • 1. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
    Abe K, Baba S, Kaneko K, Isoda T, Yabuuchi H, Sasaki M, Sakai S, Yoshino I, Honda H.
    Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review.
    Pillot G, Siegel BA, Govindan R.
    J Thorac Oncol; 2006 Feb; 1(2):152-9. PubMed ID: 17409845
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, Choi JY, Han J, Lee KS, Kim J.
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ.
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF.
    J Clin Oncol; 2008 Mar 20; 26(9):1459-64. PubMed ID: 18349396
    [Abstract] [Full Text] [Related]

  • 8. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, Vansteenkiste J.
    J Thorac Oncol; 2009 Jul 20; 4(7):822-8. PubMed ID: 19487964
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Jul 20; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 10. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, So Y, Lee DS, Chung JK, Lee MC, Kim SE.
    Eur J Radiol; 2007 May 20; 62(2):214-9. PubMed ID: 17239556
    [Abstract] [Full Text] [Related]

  • 11. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA, Demedts MG.
    J Clin Oncol; 1999 Oct 20; 17(10):3201-6. PubMed ID: 10506619
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H.
    Lung Cancer; 2016 Jan 20; 91():56-66. PubMed ID: 26711935
    [Abstract] [Full Text] [Related]

  • 13. Feasibility study of FDG PET/CT-derived primary tumour glycolysis as a prognostic indicator of survival in patients with non-small-cell lung cancer.
    Mehta G, Chander A, Huang C, Kelly M, Fielding P.
    Clin Radiol; 2014 Mar 20; 69(3):268-74. PubMed ID: 24315703
    [Abstract] [Full Text] [Related]

  • 14. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J.
    J Clin Oncol; 2008 Mar 01; 26(7):1128-34. PubMed ID: 18309948
    [Abstract] [Full Text] [Related]

  • 15. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW.
    Respirology; 2010 Nov 01; 15(8):1174-8. PubMed ID: 20573060
    [Abstract] [Full Text] [Related]

  • 16. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, Golding RP, Biesma B, Schramel FJ, van Zandwijk N, Lammertsma AA, Hoekstra OS.
    J Clin Oncol; 2005 Nov 20; 23(33):8362-70. PubMed ID: 16293866
    [Abstract] [Full Text] [Related]

  • 17. Long-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.
    Barnett S, Baste JM, Murugappan K, Tog C, Berlangieri S, Scott A, Seevanayagam S, Knight S.
    Eur J Cardiothorac Surg; 2011 Jan 20; 39(1):96-101. PubMed ID: 20580245
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R.
    J Thorac Oncol; 2008 Feb 20; 3(2):130-4. PubMed ID: 18303432
    [Abstract] [Full Text] [Related]

  • 19. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.
    Ann Thorac Surg; 2015 Feb 20; 99(2):414-20. PubMed ID: 25497068
    [Abstract] [Full Text] [Related]

  • 20. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer.
    Prévost S, Boucher L, Larivée P, Boileau R, Bénard F.
    J Nucl Med; 2006 Apr 20; 47(4):559-65. PubMed ID: 16595487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.